The Cancerguard test is a blood-based multi-cancer early detection test from Exact Sciences, the makers of Cologuard. It detects cancer signals in adults aged 50-84 using a single blood draw analyzed for circulating tumor DNA and tumor-associated protein biomarkers from more than 50 cancer types.
The test targets cancers responsible for at least 80% of U.S. diagnoses. Development study sensitivity is 64.1% at 97.4% specificity. The six deadliest cancers . pancreatic, esophageal, liver, lung, stomach, and ovarian . show 67.8% sensitivity. It costs $689 (USD) and is not FDA-approved but runs under CAP and CLIA laboratory certification.
This review examines what the Cancerguard test does, how accurately it performs in clinical studies, which adults in the 50-84 age range benefit most from the expanded screening it provides, and whether the $689 (USD) out-of-pocket price is justified by the clinical value it delivers.
What Is the Cancerguard Test?
The Cancerguard test is a blood-based multi-cancer early detection (MCED) test developed by Exact Sciences, designed to detect cancer signals in adults aged 50-84 who have not had a cancer diagnosis in the past three years. The test analyzes circulating tumor DNA and tumor-associated protein levels to identify signals associated with more than 50 cancer types.
Exact Sciences, the company behind the widely used Cologuard colorectal screening test, launched Cancerguard in 2024 as a laboratory-developed test (LDT). It is the only MCED test currently available that combines both DNA methylation analysis and protein biomarker detection.
The test is available by prescription only. Patients can request it through a telehealth provider or their primary care physician. Samples are processed at Exact Sciences Laboratories, which holds both CAP accreditation and CLIA certification for high-complexity clinical testing.
Who Is the Cancerguard Test For?
The Cancerguard test is indicated for adults between 50 and 84 years of age who have no known cancer diagnosis within the past three years and are seeking expanded screening beyond standard recommended tests. It targets the population most at risk for late-stage cancer detection.
The test is particularly relevant for adults with elevated risk factors. Smoking history, alcohol use, obesity, and age above 50 all qualify as conditions where expanded screening options like Cancerguard provide additional clinical value.
The test is not recommended for individuals who are pregnant, may become pregnant, or have had cancer within the past three years. It is also not indicated for screening breast or prostate cancer specifically, and does not evaluate precancerous lesions.
Who Makes the Cancerguard Test?
Exact Sciences develops and validates the Cancerguard test through its CAP-accredited and CLIA-certified laboratories in Madison, Wisconsin, following over two decades of cancer diagnostics research. The company is now part of Abbott following a recent acquisition.
The foundational research behind Cancerguard traces to Dr. Bert Vogelstein and colleagues at Johns Hopkins University. Early support from the Lustgarten Foundation funded the CancerSEEK prototype that directly preceded the Cancerguard platform.
Exact Sciences is best known as the maker of Cologuard, the at-home colorectal cancer screening test used by millions of Americans. Cancerguard represents the company’s expansion into broad multi-cancer detection from a single blood draw.
How Does the Cancerguard Test Work?
The Cancerguard test works by analyzing a blood sample for microscopic abnormalities in circulating tumor DNA and tumor-associated proteins that cancer cells release into the bloodstream before symptoms develop. Normal cells release small amounts of healthy DNA; cancer cells release altered DNA and protein markers that the test identifies.
A proprietary algorithm processes the combined biomarker data and returns a binary result: positive or negative. A positive result indicates a cancer signal was detected but does not confirm a cancer diagnosis. A negative result reduces but does not eliminate the possibility of cancer.
The entire process requires a single blood draw. No fasting or special preparation is needed before the test. Results return within approximately two weeks from the time the laboratory receives the sample.
What Biomarkers Does Cancerguard Detect?
Cancerguard analyzes two distinct biomarker classes simultaneously: circulating tumor DNA (ctDNA) with a focus on DNA methylation patterns, and tumor-associated protein levels in the blood. This dual approach makes it unique among currently available MCED tests.
DNA methylation refers to chemical modifications on DNA that regulate gene expression. Cancer cells display abnormal methylation patterns that differ from healthy tissue. Detecting these alterations allows the test to identify cancer presence before a tumor becomes large enough to produce symptoms.
The protein biomarker component adds a second layer of signal detection. Some cancers shed specific proteins into the bloodstream at detectable levels. Combining both signals increases sensitivity without significantly reducing specificity.
What Cancers Does Cancerguard Find?
Cancerguard detects signals associated with more than 50 cancer types and subtypes, including pancreatic, liver, lung, esophageal, ovarian, stomach, colon, uterine, kidney, head and neck, cervical, and bladder cancers. These cancers represent the types responsible for at least 80% of cancer diagnoses in the United States.
Cancers Detected by Cancerguard:
- Lung and bronchus cancer
- Colon and rectal cancer
- Pancreatic cancer
- Liver cancer
- Ovarian cancer
- Esophageal and stomach cancer
- Uterine, cervical, and kidney cancer
- Head and neck cancers
- Bladder and urinary tract cancer
The six most aggressive cancers . pancreatic, esophageal, liver, lung, stomach, and ovarian . are detected with 67.8% sensitivity at 97.4% specificity. These are the cancers with the fewest routine screening options, making the Cancerguard test most valuable for catching them early.
How Accurate Is the Cancerguard Test?
The Cancerguard test demonstrated 64.1% overall sensitivity and 97.4% specificity in a case-control development study involving 590 cancer patients and 2,434 control subjects. A separate validation study of 223 cancer patients and 800 controls confirmed 55.6% sensitivity at the same 97.4% specificity.
Cancerguard Performance Data:
| Study | Cancer Patients | Controls | Sensitivity | Specificity |
|---|---|---|---|---|
| Development study | 590 | 2,434 | 64.1% | 97.4% |
| Validation study | 223 | 800 | 55.6% | 97.4% |
| Aggressive cancers | Combined | Combined | 67.8% | 97.4% |
The 97.4% specificity means the test produces a false positive in roughly 2.6 out of every 100 tests. For a population screening context, this rate is considered clinically acceptable. Follow-up imaging resolves most false positive findings without requiring invasive procedures.
What Is the Sensitivity of the Cancerguard Test?
Sensitivity of 64.1% means Cancerguard detects approximately 64 out of every 100 existing cancers in the tested population, with the remaining 36 producing negative results despite cancer being present. This is a real limitation that patients and physicians must factor into clinical decision-making.
Worth noting: these figures come from case-control studies. Real-world sensitivity in a general screening population may differ from results in study populations selected for known cancer presence. How the test performs in broader screening programs is still being evaluated through ongoing prospective studies.
For comparison, standard colorectal screening via Cologuard detects about 92% of colorectal cancers. Cancerguard covers far more cancer types but at lower per-type sensitivity. The trade-off is expanded coverage versus depth of detection for any single cancer type.
What Does a False Positive Mean?
A false positive Cancerguard result means the test detected a cancer signal in the blood but subsequent imaging and clinical evaluation found no cancer present. Patients receive positive results with a recommended follow-up imaging pathway regardless of whether cancer is ultimately confirmed.
The standard follow-up after a positive result begins with blood tests including a complete blood count and comprehensive metabolic panel. If those results warrant further investigation, contrast-enhanced CT imaging of the chest, abdomen, pelvis, and soft-tissue neck is the next step.
Exact Sciences’ modeling data predicts the imaging-led workflow reduces the burden of diagnostic procedures by approximately 30% (30%) compared to less structured follow-up approaches. Patients requiring deeper investigation progress to PET-CT from skull base to mid-thigh if CT findings remain inconclusive.
What Are the Benefits of the Cancerguard Test?
The Cancerguard test expands cancer screening coverage to types that account for roughly 70% of cancer deaths in the United States, most of which have no currently recommended routine screening options. A single blood draw replaces the absence of screening entirely for these cancers.
Modeling data project that adding Cancerguard to standard-of-care screening could reduce stage IV cancer incidence by 42% over a ten-year timeframe. Stage IV cancer is dramatically harder to treat and carries significantly lower survival rates than Stage I or II diagnoses.
The test integrates with existing healthcare workflows without invasive procedures or special preparation. Patients with increased risk factors get actionable information from a routine blood draw, and providers receive a clear positive or negative result within two weeks.
Does Cancerguard Find Cancer Before Symptoms Appear?
Yes. Cancerguard detects altered DNA and protein markers in the bloodstream before tumors grow large enough to produce physical symptoms, which is the core clinical value proposition of multi-cancer early detection testing. Earlier detection corresponds directly to higher treatment success rates.
When cancer is found at an early stage before it spreads, the chances of effective treatment increase significantly. Many of the cancers Cancerguard targets . pancreatic, ovarian, liver . are almost always diagnosed at late stages under current screening protocols because no routine early detection method existed before MCED tests.
The Lustgarten Foundation-supported CancerSEEK research that preceded Cancerguard was designed specifically around the premise that blood-based cancer signals appear before clinical symptoms. Exact Sciences built its commercial version on this validated biological foundation.
Does Cancerguard Replace Other Cancer Screenings?
No. Cancerguard is designed to complement, not replace, existing recommended cancer screenings including mammograms, colonoscopies, Pap smears, and low-dose CT lung screening for high-risk smokers. The product labeling explicitly states this limitation.
Cancerguard is not indicated for screening breast or prostate cancers . two of the most common cancer types . because those have established, dedicated screening protocols. The test fills gaps in coverage, not overlap with existing methods.
Patients who receive a negative Cancerguard result should continue following all other screening recommendations from their healthcare provider. A negative result does not rule out cancer of any type, including types the test is designed to detect.
What Do Cancerguard Test Reviews Say?
The Cancerguard test draws strong support from oncologists and early detection researchers who recognize the clinical significance of MCED technology, while patient-facing reviews reflect both gratitude for expanded options and concern about the cost and follow-up burden.
The Lustgarten Foundation, a leading pancreatic cancer research organization, publicly endorsed the foundational science behind Cancerguard’s development. Medical professionals treating pancreatic and ovarian cancer patients . cancers historically caught too late . express the strongest clinical enthusiasm.
Independent reviewers note the gap between the test’s real-world performance in case-control studies versus how it may perform in general population screening. The validation study’s 55.6% sensitivity is meaningfully lower than the development study, which raises questions about consistency across broader populations.
What Are the Positive Experiences?
Patients and providers most consistently praise Cancerguard for giving high-risk individuals a proactive screening option where none previously existed, particularly for pancreatic, liver, and ovarian cancers. The simple blood draw format removes the procedural barriers of more invasive screening methods.
Key Benefits Reported by Users and Providers:
- Simple blood draw with no fasting or preparation required
- Results available within two weeks
- Detects cancers with no other routine screening method
- HSA and FSA eligible, reducing out-of-pocket cost impact
- Care navigation support after a positive result
- Available through Quest Diagnostics at approximately 7,000 locations
The Expert-designed imaging resolution pathway also draws positive feedback from providers. Having a structured follow-up protocol reduces physician uncertainty after a positive result and improves patient experience through a well-defined process.
What Are the Common Concerns?
The most common concern about Cancerguard is its $689 (USD) self-pay price point and the lack of routine insurance coverage, which limits access to the test for many of the adults who would benefit most from expanded cancer screening.
Common Concerns:
- $689 (USD) out-of-pocket cost with no standard insurance coverage
- Not FDA-cleared or approved . offered as a laboratory-developed test
- Validation study sensitivity (55.6%) lower than development study (64.1%)
- Positive results require follow-up imaging that adds time, cost, and anxiety
- Not available in all states . currently not offered in New York state
- Does not screen for breast or prostate cancer
The FDA review status concerns some patients and providers. Exact Sciences operates Cancerguard under CLIA and CAP laboratory regulations, which is lawful for laboratory-developed tests. However, an FDA-cleared test would provide an additional layer of regulatory validation that currently does not exist for this product.
Is the Cancerguard Test Safe?
The Cancerguard test carries the standard risks of a routine blood draw and poses no independent health risks beyond the venipuncture procedure itself, as it is a passive analysis of an already-collected blood sample. The test introduces no substances into the body.
The main safety consideration lies downstream of a positive result. Contrast-enhanced CT imaging, the standard follow-up imaging, uses iodine-based intravenous contrast that poses risk for patients with contrast allergy or kidney disease. The product labeling explicitly flags this concern.
Exact Sciences provides care navigation support for patients who receive positive results. This service helps coordinate the follow-up imaging process and ensures patients are not left without guidance after a potentially stressful positive finding.
What Are the Risks of the Cancerguard Test?
The primary risk of the Cancerguard test is a false positive result that triggers unnecessary follow-up imaging and the associated radiation exposure, contrast agent risks, and patient anxiety of pursuing a cancer diagnosis that ultimately does not exist. Approximately 2.6 in 100 tests return a false positive.
False negative results carry a different kind of risk. A negative Cancerguard result may create false reassurance in patients who reduce adherence to other recommended screenings. The test labeling explicitly states that a negative result does not rule out cancer of any type.
For patients with iodine contrast allergies or kidney conditions that increase contrast nephropathy risk, the follow-up imaging pathway after a positive result carries additional medical considerations. Providers must evaluate these factors before ordering the test.
Who Should Not Take the Cancerguard Test?
Women who are pregnant, may become pregnant, or plan to become pregnant should not use the Cancerguard test due to radiation exposure risks in the contrast CT follow-up pathway required after a positive result. The product labeling lists pregnancy as a specific contraindication.
Adults under 50 or over 84 fall outside the indicated age range. The test was evaluated specifically in the 50-84 demographic, and its performance data does not apply to patients outside this range. Ordering the test for patients outside this age group is off-label.
Patients with a cancer diagnosis within the past three years should also avoid the test. The presence of active cancer treatment or recent remission creates blood biomarker patterns that fall outside the test’s validated interpretation framework.
How Much Does the Cancerguard Test Cost?
The Cancerguard test costs $689 (USD) as a self-pay price, with HSA (Health Savings Account), FSA (Flexible Spending Account), and HRA (Health Reimbursement Arrangement) programs accepted as payment methods. Standard health insurance does not currently cover the test.
The $689 price covers the laboratory analysis, result delivery, and access to the care navigation program. Follow-up imaging costs after a positive result are separate and depend on the individual’s insurance plan and the imaging facility used.
Results are typically available within two weeks. The test is available through Quest Diagnostics at approximately 7,000 patient service sites across the United States, as well as through mobile phlebotomy options for patients who prefer at-home blood draws.
Is the Cancerguard Test Worth the Price?
For adults in the 50-84 age range with elevated risk factors, Cancerguard represents meaningful clinical value at $689 (USD) because it provides early detection coverage for cancer types that currently have no routine screening alternative. The math changes depending on individual risk profile.
Consider this: pancreatic cancer has a 5-year survival rate of about 12% when diagnosed at Stage IV. At Stage I, that rate climbs to 44%. If Cancerguard catches a pancreatic cancer signal early, the $689 investment buys an entirely different treatment trajectory.
For adults with low risk factors and consistent adherence to existing screening guidelines, the incremental benefit is smaller. The test fills gaps in coverage for specific high-mortality cancers. The stronger the risk profile, the more justified the expense becomes.
Where Can You Get the Cancerguard Test?
The Cancerguard test is available at approximately 7,000 Quest Diagnostics patient service sites nationwide, with mobile phlebotomy options available for patients who prefer an at-home blood draw. It requires a prescription from a physician or telehealth provider.
Patients can request the test directly through a telehealth visit on Cancerguard.com without seeing their regular physician first. The telehealth option accelerates access for adults who want to initiate screening independently before their next annual appointment.
The test is currently not available in New York state pending state-specific regulatory approval. Exact Sciences maintains an email list for New York residents to receive notification when availability opens in that state.
Is the Cancerguard Test Worth It?
The Cancerguard test is worth serious consideration for adults aged 50-84 with elevated cancer risk who want expanded detection coverage beyond what standard screenings currently offer. Its greatest value lies in detecting the deadliest cancers before symptoms appear.
Here’s the thing. The test is not FDA-approved, costs $689 (USD), and catches about 64% of cancers in study populations. Those are real limitations. But for pancreatic, ovarian, and liver cancers . the ones that kill because they’re caught too late . having any early detection signal is better than having none at all.
The right candidates are adults in the indicated age range, with risk factors, who already follow all other recommended screening protocols. For that group, Cancerguard adds a meaningful layer of surveillance that no other single test currently provides. Talk to a physician before ordering to confirm the test is appropriate for the individual clinical picture.